# NM_000798.5(DRD5):c.262C>T (p.Leu88Phe)

https://sugi.bio/variant/drd5-p-leu88phe

## Summary

**DRD5 p.Leu88Phe (c.262C>T)** is classified **Benign** in DRD5 (ClinVar, Multiple submitters, 3 submitters; last evaluated 2017-07-27). AlphaMissense: likely benign (0.1765); Rare (popmax 0.897%, nfe).

**At a glance:** Benign · review: Multiple submitters · rsID rs148402761 · 3 submitters · AlphaMissense likely benign · rare (popmax 0.897%, nfe)

## For patients & families {#patients}

This is a change in the DRD5 gene that is classified as benign — not considered disease-causing, submitted by 3 submitters.

*Reference information, not medical advice, and not a prediction for any individual. A genetic counselor or clinician can interpret what it means for you and your family.*

**Support & next steps:** [Find a genetic counselor (NSGC)](https://findageneticcounselor.nsgc.org/).

## Identity {#identity}

| Field | Value |
| --- | --- |
| Gene | [DRD5](https://sugi.bio/atlas/gene/DRD5/) |
| Protein change (HGVS p.) | p.Leu88Phe |
| Coding change (HGVS c.) | c.262C>T |
| MANE Select transcript | [NM_000798](https://www.ncbi.nlm.nih.gov/nuccore/NM_000798) |
| dbSNP | [rs148402761](https://www.ncbi.nlm.nih.gov/snp/rs148402761/) |
| Variant type | single nucleotide variant |
| Location | chr4:9782291-9782291 (GRCh38) |
| ClinVar | [VCV592325](https://www.ncbi.nlm.nih.gov/clinvar/variation/592325/) |

**All HGVS expressions:** `NC_000004.11:g.9783915C>T`, `NC_000004.12:g.9782291C>T`, `NG_012024.1:g.5658C>T`, `NM_000798.4:c.262C>T`, `NM_000798.5:c.262C>T`

## Computational & population evidence {#evidence}

**Concordance:** Mixed / partial computational evidence (see below).

- AlphaMissense **likely benign** (0.1765)
- REVEL 0.515 (indeterminate)
- SaProt LLR -7.701 (tolerated) — agrees with AlphaMissense
- → **In-silico consensus:** AlphaMissense and SaProt both call this tolerated; REVEL makes no call
- Conservation: phyloP 4.578, GERP 1.84, phastCons 1 — highly conserved (differs from AlphaMissense)
- CADD: **PHRED 25.5**. No single ClinGen-calibrated threshold exists and the expert panels that use CADD disagree — GUCY2D/AIPL1 require ≥ 20.0 for an untranslated-region variant, ABCA4 ≥ 28.1 for a synonymous or indel variant, the Pulmonary Hypertension panel imports Pejaver 2022's missense-calibrated numbers, and the Antibody Deficiencies panel declines CADD entirely for PIK3CD. CADD v1.7 also incorporates Zoonomia phyloP, so it partly re-expresses the conservation above. *Descriptive; no threshold applied.*
- Regional missense constraint: **o/e 1.15** across the covering region of the MANE Select transcript (9,782,030–9,783,460), spanning 1,430 bp. Chi-square p 9.4e-05. Describes the region, not this allele; gnomAD v4.1.1's own constrained determination. *Descriptive; no ACMG code applied.*
- SpliceAI: **not assessed** — no allele at this position is in our SpliceAI release, either because it lies outside the scored MANE transcript scope or because every allele is below Δ0.2. We cannot tell which, so this claims neither; absence is not evidence against a splicing effect.
- Population frequency (gnomAD v4.1): grpmax **0.897%** (nfe) · FAF95 0.883% · FAF99 0.877% · 10,582/1,179,882 in the highest group · 11,727/1,614,012 alleles overall — rare (popmax 0.897%, nfe).

| Ancestry group | Allele frequency | 1 in |
| --- | --- | --- |
| Amish (not grpmax-eligible) | 1.1% | 91 |
| European (non-Finnish) (grpmax) | 0.897% | 111 |
| Admixed American | 0.76% | 132 |
| Remaining individuals (not grpmax-eligible) | 0.618% | 162 |
| Middle Eastern | 0.182% | 549 |
| African / African-American | 0.147% | 682 |
| South Asian | 0.101% | 990 |
| Finnish (not grpmax-eligible) | 0.0906% | 1,104 |
| East Asian | 0.0379% | 2,640 |
| Ashkenazi Jewish (not grpmax-eligible) | 0.0169% | 5,921 |

Amish shows a higher raw frequency than the grpmax group. gnomAD excludes bottlenecked groups — Finnish, Ashkenazi Jewish, Amish and "Remaining individuals" — from grpmax, because founder effects make their frequencies unrepresentative for filtering. The table is sorted by frequency, so an excluded group can sit above the grpmax row.

*Computational predictors are not independent (ClinGen Variant Classification guidance): AlphaMissense (Cheng et al. 2023) carries the ACMG weight for missense and conservation (phyloP/GERP/phastCons) for non-missense; REVEL (Pejaver-2022 calibrated strength bands) and SaProt (Su et al. 2023, structure-aware, ClinVar-independent protein language model, raw LLR) are shown as orthogonal agreement signals, not additive. For frequency, the gnomAD v4.1 grpmax filtering allele frequency (FAF95) is ClinGen's designated BA1/BS1 input (gnomAD v4 guidance v3.0, June 2025); BA1/BS1 thresholds are disease-specific, not a blanket 5%. Predictions, not a clinical determination.*

## Gene constraint & dosage {#gene-context}

**DRD5** population constraint: LOEUF 1.851, pLI 0.094369, missense-Z -1.3312; ClinGen dosage — haploinsufficiency 0, triplosensitivity 0 (0–3 scale). *Lower LOEUF and higher pLI indicate a gene that tolerates loss-of-function poorly; ClinGen dosage is the curated haploinsufficiency call.*

## Protein context {#protein}

Residue **88** lies in a UniProt-annotated variant site (in); an α-helix.

AlphaFold model confidence (whole protein): pLDDT 69.45, 31% of residues very-high.

**1 experimental structure(s)** (PDB): [8IRV](https://www.rcsb.org/structure/8IRV).

## What this gene does {#gene-function}

*Describes the biological roles of DRD5 (the gene this variant disrupts) — not effects measured for this specific variant. A damaging variant is expected to affect these functions and pathways; the degree depends on the variant.*

**How this variant is thought to act:** DRD5's established molecular role includes dopamine neurotransmitter receptor activity.


### Pathways affected {#pathways}

DRD5 participates in **2 Reactome pathways** (⚕ = disease pathway):

| Pathway (Reactome) | Evidence |
| --- | --- |
| [Dopamine receptors](https://reactome.org/content/detail/R-HSA-390651) | curated |
| [G alpha (s) signalling events](https://reactome.org/content/detail/R-HSA-418555) | curated |

### Molecular function & processes (GO — experimentally supported) {#go}

**Molecular function:** dopamine neurotransmitter receptor activity, dopamine binding.

**Biological process:** adenylate cyclase-activating G protein-coupled receptor signaling pathway, adenylate cyclase-activating dopamine receptor signaling pathway, regulation of blood pressure, cellular response to catecholamine stimulus, reactive oxygen species metabolic process.

## Clinical significance {#significance}

**Benign** — review status Multiple submitters *(criteria provided, multiple submitters, no conflicts)*, last evaluated 2017-07-27.

**Submitter consensus:** unanimous (3/3 Benign).

**Submission history:** 3 submissions (2017–2019); classifications have been stable.

### Submitter classifications {#submitters}

| Submitter | Classification | Review | Method | Date |
| --- | --- | --- | --- | --- |
| Eurofins Ntd Llc (ga) | Benign | criteria provided, single submitter | clinical testing | 2017-07-27 |
| PreventionGenetics, part of Exact Sciences | Benign | no assertion criteria provided | clinical testing | 2019-10-31 |
| Breakthrough Genomics, Breakthrough Genomics | Benign | criteria provided, single submitter | not provided |  |

**Reported phenotype names (ClinVar):** not specified, not provided, DRD5-related disorder, none provided, RECLASSIFIED - ADRA2C POLYMORPHISM, RECLASSIFIED - ADRB1 POLYMORPHISM, DRD5-related condition, AllHighlyPenetrant.

## Similar variants {#similar}

Related DRD5 variant pages (same residue, condition, or type): [DRD5 p.Val59Met](/variant/drd5-p-val59met), [DRD5 c.-226G>C](/variant/drd5-c-minus-226g-c), [DRD5 c.*178G>T](/variant/drd5-c-star-178g-t), [DRD5 c.*47T>C](/variant/drd5-c-star-47t-c), [DRD5 p.Ala10Val](/variant/drd5-p-ala10val), [DRD5 p.Ala111Glu](/variant/drd5-p-ala111glu), [DRD5 p.Ala164Glu](/variant/drd5-p-ala164glu), [DRD5 p.Ala16Pro](/variant/drd5-p-ala16pro).

### Data sources & attribution {#sources}

ClinVar (NCBI — public domain, built 2026-10-11); gnomAD v4.1 (Broad Institute, built 2026-10-06); AlphaMissense (Cheng et al. 2023, © Google DeepMind — CC BY 4.0, built 2026-01-27); REVEL (Ioannidis et al. 2016 — ODbL, built 2026-07-13); SaProt (Su et al. 2023 — MIT, built 2026-07-14); SpliceAI (Illumina — free for non-commercial use, built 2026-10-13); CADD (Rentzsch et al. 2019, University of Washington — free for non-commercial use, built 2026-10-10); Conservation (phyloP/phastCons/GERP) (UCSC hg38 470-way mammal (Hiller Lab) + Ensembl Compara, built 2026-07-12); gnomAD Non-coding Constraint (Gnocchi) (Chen et al. 2024, Broad Institute — CC0, built 2026-10-11); gnomAD Regional Missense Constraint (Broad Institute — CC0, built 2026-10-13); Pangolin (Zeng & Li 2022 — CC BY 4.0, built 2026-10-11); Repeat regions (UCSC — RepeatMasker, TRF, segmental duplications, built 2026-10-11); ClinGen (ClinGen, built 2026-09-22); UniProt (CC BY 4.0); Reactome / GO (CC BY 4.0, built 2026-09-23); MaveDB (per-record license, built 2026-10-11); CIViC (CC0, built 2026-09-22); Orphanet (Orphanet, built 2026-06-12)

*Primary record: NCBI ClinVar (variation 592325). Classifications reflect these databases as of the page's build date and may change. Free reference use — not medical advice; consult the primary submitters and a clinician.*